Non-Q wave and ST segment depression myocardial infarction: is there a role for thrombolytic therapy?

[1]  A. Skene,et al.  Late assessment of thrombolytic efficacy (LATE) study: Prognosis in patients with non-Q wave myocardial infarction , 1996 .

[2]  J. Mcmanus.  Effects of tissue plasminogen activator and a comparison of early invasive and conservative strategies in unstable angina and non-Q-wave myocardial infarction: Results of the TIMI IIIB trial: The TIMI IIIB Investigators Circulation 89:1545–1556 Apr 1994 , 1994 .

[3]  C. Fry,et al.  Science of urinary incontinence Report of a Meeting of Physicians and Scientists, University College London , 1994, The Lancet.

[4]  L. Wilkins.  Effects of tissue plasminogen activator and a comparison of early invasive and conservative strategies in unstable angina and non-Q-wave myocardial infarction. Results of the TIMI IIIB Trial. Thrombolysis in Myocardial Ischemia. , 1994, Circulation.

[5]  Johan Herlitz,et al.  Indications for fibrinolytic therapy in suspected acute myocardial infarction : collaborative overview of early mortality and major morbidity results from all randomised trials of more than 1000 patients , 1994 .

[6]  L. Wilkins.  Early Effects of Tissue‐Type Plasminogen Activator Added to Conventional Therapy on the Culprit Coronary Lesion in Patients Presenting With Ischemic Cardiac Pain at Rest Results of the Thrombolysis in Myocardial Ischemia (TIMI IIIA) Trialx , 1993, Circulation.

[7]  E. Braunwald,et al.  Myocardial reperfusion, limitation of infarct size, reduction of left ventricular dysfunction, and improved survival. Should the paradigm be expanded? , 1989, Circulation.

[8]  A. M. Skene,et al.  TRIAL OF TISSUE PLASMINOGEN ACTIVATOR FOR MORTALITY REDUCTION IN ACUTE MYOCARDIAL INFARCTION Anglo-Scandinavian Study of Early Thrombolysis (ASSET) , 1988, The Lancet.

[9]  Sarah Parish,et al.  Randomized trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2.ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. , 1988, Journal of the American College of Cardiology.

[10]  Dwight E. Peake,et al.  Thrombolysis in myocardial infarction (TIMI) trial: Phase I. A comparison between intravenous tissue plasminogen activator and intravenous streptokinase , 1988 .

[11]  R Roberts,et al.  Thrombolysis in Myocardial Infarction (TIMI) Trial, Phase I: A comparison between intravenous tissue plasminogen activator and intravenous streptokinase. Clinical findings through hospital discharge. , 1987, Circulation.

[12]  Harold T. Dodge,et al.  Thrombolysis inMyocardial Infarction (TIMI) Trial, Phase I:acomparison between intravenous tissue plasminogen activator andintravenous streptokinase* , 1987 .

[13]  Y. Ohtsuki,et al.  ISOLATION OF HTLV-I FROM CEREBROSPINAL FLUID OF A PATIENT WITH MYELOPATHY , 1986, The Lancet.

[14]  T. P. Judge,et al.  Coronary arteriographic findings soon after non-Q-wave myocardial infarction. , 1986, The New England journal of medicine.

[15]  Gruppo Italiano per lo Studio della Soprawivenza nell'Inf Miocardico..  EFFECTIVENESS OF INTRAVENOUS THROMBOLYTIC TREATMENT IN ACUTE MYOCARDIAL INFARCTION , 1986, The Lancet.

[16]  M S Golden,et al.  Prevalence of total coronary occlusion during the early hours of transmural myocardial infarction. , 1980, The New England journal of medicine.

[17]  J. Lowe,et al.  The Wavefront Phenomenon of Ischemic Cell Death: 1. Myocardial Infarct Size vs Duration of Coronary Occlusion in Dogs , 1977, Circulation.

[18]  T. Waterston.  Fluids for diarrhoea in young children. , 1977, Lancet.

[19]  E. Veys,et al.  Letter: HL-A and infective sacroileitis. , 1974, Lancet.

[20]  S. Gilder.  Home or Away. , 1964, Canadian Medical Association journal.